Resonance Health Share Price and Company Fundamentals
Last traded: Yesterday at 1:49 AM
Resonance Health Limited, a healthcare technology and services company, designs, develops, and manufactures software-as-medical devices in the Asia Pacific, North America, South America, Europe, the Middle East, and Africa. It offers FerriScan, a non-invasive MRI based system for quantifying liver iron concentration (LIC); FerriSmart, an artificial intelligence (AI) assisted device for the automated real-time assessment of LIC; HepaFat-AI, an AI-assisted device for the automated real-time multi-metric measurement of liver-fat; CardiacT2, a dual analysis service with FerriScan for assessing heart iron loading; HepaFat-Scan, a non-invasive MRI-based solution for the assessment of liver-fat in liver tissue; and LiverSmart, a non-invasive MRI-based multi-parametric device combining FerriSmart and HepaFat-AI into a consolidated report. It also offers quantitative imaging measurements and CRO, such as quality-assured image analysis, imaging charter development, project and data management, issue resolution, site tracker and clinical trial progress report, and coordination of data flow services; biomarkers, blood, urine, and protein analytes, as well as RNA, DNA, and genotyping services; and protocol development, assessment of subject inclusion or exclusion, decisions on dose modifications, and evaluating the safety profile of a new therapy, as well as supporting primary and secondary end-points demonstrating drug efficacy services for multinational and multicenter clinical trials; and phantoms for the calibration of MRI machines. The company serves clinicians for the management of human diseases; and pharmaceutical and therapeutic companies for their clinical trials. Resonance Health Limited was incorporated in 1987 and is headquartered in Burswood, Australia.
|Primary activities||Medical Device Software|
|Industry / Sector||Health Information Services / Healthcare|
|Mailing address||141 Burswood Road Burswood WA 6100 Australia|
|Phone / Fax||61 8 9286 5300 / 61 8 9286 5399|
|Share registry||ADVANCED SHARE REGISTRY SERVICES|
Resonance Health paid $0.00 dividend and the ex-dividend date was .The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.RHT dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
RHT's forward dividend amount is $ and the forward dividend yield is . A forward dividend yield is the percentage of a company's current stock price that it expects to pay out as dividends over a certain time period, generally 12 months. Forward dividend yields are generally used in circumstances where the yield is predictable based on past instances. If not, trailing yields, which indicate the same value over the previous 12 months, are used.
As of Oct 2022, following are the company executives and directors listed on Resonance Health.
|Mr. Mitchell M. Wells B.Com., B.Comm, L.L.B., LLB||MD, Joint Company Sec. & Exec. Director||46||150.5k|
|Mr. Nicholas Allan A.C.A., B.Com.||CFO, COO & Joint Company Sec.||209.34k|
|Mr. Ben Winters||Chief Technology Officer|
|Mr. Chad Tondut||Communications Mang. and GM of Products & Portfolio|
|Mr. Ajay Nair||Gen. Mang. of Global Sales & Marketing|
|Dr. John Olynyk BMedSc, FRACP, M.D., MBBS||Chief Medical Officer|
|Dr. Timothy Guy St. Pierre B.Sc(Hons), Ph.D.||Chief Research Scientist|
|Dr. Wenjie Pang Ph.D.||Chief Scientific Officer Imaging & AI|
|Dr. Sherif Boulos Ph.D.||Chief Scientific Officer of Molecular|
|Ms. Liesl Ellies||Joint Company Sec.|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Resonance Health is and its enterprise value is .
The RHT's stocks Beta value is 1.02 making it 2% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Resonance Health (RHT)
- Ansell (ANN)
- Cochlear (COH)
- Fisher & Paykel Healthcare Corporation (FPH)
- Estia Health (EHE)
- Healius (HLS)
- Nanosonics (NAN)
- Pro Medicus (PME)
- Resmed Inc (RMD)
- Ramsay Health Care (RHC)
- Polynovo (PNV)
- Sonic Healthcare (SHL)
Resonance Health (ASX:RHT) Frequently Asked Questions
1. What is Resonance Health's Stock Symbol?
Resonance Health trades on ASX under the ticker symbol "RHT".
2. What is Resonance Health's stock price today?
One share of RHT stock can currently be purchased for approximately $0.053.
3. How can I contact Resonance Health?
Resonance Health's mailing address is 141 Burswood Road Burswood WA 6100 Australia. The company can be reached via phone at 61 8 9286 5300.
4. What is Resonance Health's official website?
The official website of Resonance Health is https://www.resonancehealth.com.
5. Which share registry manages Resonance Health's stock?
Resonance Health's stock is managed by ADVANCED SHARE REGISTRY SERVICES.